Therapeutic advances in medical oncology

Ovarian clear cell carcinoma (OCCC) is a distinct epithelial ovarian cancer subtype with unique molecular features, and a notable resistance to conventional platinum-based chemotherapy in advanced disease. Key molecular hallmarks include fr…

Epithelial ovarian cancer (OC) comprises molecularly distinct disease types, with high-grade serous ovarian cancer (HGSOC) accounting for ~75% of OC diagnoses; ovarian clear cell carcinoma (OCCC) and endometrioid ovarian carcinoma (EnOC) at…

BACKGROUND: A newly generic microspheres, sustained-release formulation of triptorelin acetate 3.75 mg has been developed. OBJECTIVES: To evaluate the efficacy, pharmacokinetics, and safety of triptorelin 1-month formulation in Chinese pat…

The treatment of high-grade serous ovarian cancer and high-grade endometrioid ovarian cancer has seen significant improvements in recent years, with BRCA1/2 and homologous recombination status guiding a personalized approach which has resul…

BACKGROUND: Although ataxia-telangiectasia and Rad3 related (ATR) has an established role in the DNA damage response of various cancers, its clinical and prognostic significance in ovarian cancer remains largely unknown. The aims of this st…

Tissue inhibitor of metalloproteinase-3 (TIMP-3), a secreted glycoprotein, plays an important role in carcinogenesis. It can bind to many proteinases to suppress their activity and thus protect the extracellular matrix from degradation. TIM…